AMERICAN SOCIETY FOR COLPOSCOPY OF CERVICAL PATHOLOGY CONFERENCE (ASCCP 2020)

The ASCCP was founded in 1964 as a non-profit specialty society. Since then, the ASCCP has been the leading source of post-graduate training in colposcopy not only in the United States, but throughout the world.

The ASCCP 2020 Virtual Scientific Meeting on anogenital and HPV-related diseases is an interdisciplinary meeting with healthcare professionals in the areas of Obstetrics and Gynaecology, as well as industry representatives.

Below you will find the efficacy results of PAPILOCARE® presented during the ASCCP 2020.

1. NORMALISATION OF LESIONS AND VIRAL CLEARANCE

Efficacy of PAPILOCARE® in the reparation of low-grade cervical lesions and viral clearance in patients with the presence of high-risk HPV. Presented by Gilles Seydoux, General Manager Procare Health US

2. RE-EPITHELIALISATION, STRESS AND TOLERABILITY

Effect of PAPILOCARE® on cervical re-epithelialisation and quality of life of treated patients. Presented by Seydoux Gilles, General Manager Procare Health US

3. PAPILOBS: A REAL-LIFE OBSERVATIONAL STUDY

Intermediate results of PAPILOCARE® in the repair of low-grade cervical lesions and viral clearance in a real-life study. Explained by Carine Emsellem, Medical Director of Procare Health.

4. CORROBORATED RESULTS

The efficacy of PAPILOCARE® in clearing high-risk HPV has been corroborated in 6 studies and more than 700 patients. Presented by Yann Gaslain, CEO of Procare Health Iberia

5. PAPILLOSCOPY SURVEY: MANAGEMENT OF VPH-POSITIVE PATIENTS

Results from a survey completed by specialists with experience in the management of HPV-positive patients over 30 years of age in Spain. Presented by Carine Emsellem, Medical Director of Procare Health.

6. PERSISTENCE OF HIGH-RISK VPH

Actual data of high-risk HPV persistence in patients who followed the standard clinical practice of watchful waiting in the metropolitan area of Barcelona. Explained by Dr. Margarita Riera, Milenium Centro Médico Balmes,